US Says Novo Nordisk Lacks Power to Attack Drug Price Program

Novo Nordisk’s constitutional challenges against a government drug price-setting scheme are unfit for review, the Department of Justice told a federal court.

The US Department of Justice, representing the Medicare agency in the legal fray between the pharmaceutical industry and the administration over the Drug Price Negotiation Program, urged the US District Court for the District of New Jersey to dismiss the drugmaker’s challenge.

Among its arguments in a cross motion for summary judgment filed Jan. 26 are that Novo Nordisk’s challenge are “unreviewable” by the court, citing President Joe Biden’s 2022 Inflation Reduction Act. Under the law, the ...